Xeloda 500mg (Capecitabine Tablet) 500mg

Capecitabine, the active ingredient in Xeloda 500mg, is a prodrug that is metabolized to 5-fluorouracil. It inhibits thymidylate synthase, which interferes with DNA synthesis in rapidly dividing tumor cells, thereby slowing or stopping the growth of cancer cells.

The usual dose of Xeloda 500mg is determined by a healthcare professional based on the patient's body surface area and the specific condition being treated. It is typically taken orally twice daily for two weeks, followed by a one-week rest period.

Xeloda 500mg is not recommended during pregnancy as it can harm the fetus. It is also not recommended during breastfeeding due to the potential risks to the infant. Always consult a healthcare professional for personalized advice.

To order Xeloda 500mg from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will then provide pricing, availability, shipping, and the necessary import paperwork.

Xeloda 500mg is an oral chemotherapy agent that offers convenience for patients who prefer not to receive intravenous treatments. It is effective in treating specific types of cancer and is often used in combination with other therapies. The choice of treatment depends on the type and stage of cancer, as well as the patient's overall health.

Xeloda 500mg should be stored below 25°C, kept in the original pack, and protected from moisture. It should be handled with care, and any broken or damaged tablets should be disposed of properly. Always follow the storage instructions provided by the manufacturer.

Xeloda 500mg is taken orally, typically twice daily for two weeks, followed by a one-week rest period. The tablets should be swallowed whole with water within 30 minutes after the end of a meal. Do not crush, chew, or cut the tablets.

The most serious risks associated with Xeloda 500mg include cardiotoxicity, bone marrow suppression, severe diarrhea, severe stomatitis, neutropenia, and thrombocytopenia. Patients should be monitored closely for these side effects, and any severe reactions should be reported to a healthcare professional immediately.

Xeloda 500mg should not be taken by individuals who are allergic to capecitabine, 5-fluorouracil, or any ingredients of the medication. It should also be avoided by patients with dihydropyrimidine dehydrogenase (DPD) deficiency, severely reduced kidney function, or those being treated with brivudine or sorivudine.